Ostwald, France

Michel Obringer


 

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 64(Granted Patents)


Company Filing History:


Years Active: 2016-2017

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Michel Obringer: Innovator in Naphthyridine Derivative Compounds

Introduction

Michel Obringer is a notable inventor based in Ostwald, France. He has made significant contributions to the field of pharmaceuticals, particularly through his work on naphthyridine derivative compounds. With a total of three patents to his name, Obringer's innovations are paving the way for advancements in the treatment of various diseases, including cancer.

Latest Patents

Obringer's latest patents focus on new naphthyridine derivative compounds. These inventions relate to pharmaceutical compositions that comprise these compounds, as well as processes for their preparation. The compounds are intended for use in the treatment of diseases, such as cancer, showcasing their potential therapeutic applications.

Career Highlights

Michel Obringer is currently associated with Astex Therapeutics Limited, where he continues to develop innovative solutions in the pharmaceutical industry. His work is characterized by a commitment to improving health outcomes through scientific research and development.

Collaborations

Throughout his career, Obringer has collaborated with esteemed colleagues, including Matthieu Ludovic Jeanty and Patrick Rene Angibaud. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

In summary, Michel Obringer is a distinguished inventor whose work on naphthyridine derivative compounds is making a significant impact in the pharmaceutical field. His contributions are essential for the ongoing fight against diseases like cancer, and his collaborations further enhance the potential of his innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…